Clinical Trials Logo

Jaundice, Obstructive clinical trials

View clinical trials related to Jaundice, Obstructive.

Filter by:

NCT ID: NCT03416062 Completed - Jaundice; Malignant Clinical Trials

Remaxol® in Malignant Mechanical Jaundice

Start date: April 3, 2017
Phase: Phase 3
Study type: Interventional

The trial intends to study the safety and efficacy of Remaxol® (succinate + methionine + inosine + nicotinamide; POLYSAN Ltd., Russia),solution for infusion for the reduction of hyperbilirubinemia in patients with obstructive jaundice caused by tumor (malignancy).

NCT ID: NCT03376945 Completed - Clinical trials for Surgical Procedure, Unspecified

Application of n-3 Fatty to Patient of Jaundice

Start date: January 1, 2014
Phase: N/A
Study type: Observational

The safety and efficacy of ω-3 fatty acid in patients with obstructive jaundice is not known. This study provided evidences that ω-3 fatty acid-based parenteral nutrition improved postoperative recovery for patients with obstructive jaundice.

NCT ID: NCT02721277 Completed - Cholestasis Clinical Trials

SMOFlipid to Lessen the Severity of Neonatal Cholestasis

Start date: May 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Parenteral nutrition (PN) provides intravenous nutritional supplementation for infants unable to absorb adequate enteral nutrients secondary to insufficient intestinal length or function. In early PN-associated cholestasis, the dose of traditional soy based lipid is limited to 1 g/kg/day which often limits the growth capacity of parenteral nutrition-dependent infants. Inadequate growth is directly related to poor neurological outcomes, failure to facilitate mechanical ventilation, and less growth of the neonate's already damaged intestine. Ultimately, these outcomes can lead to severe disability and death. To mitigate these deleterious effects and optimize growth, parenteral nutrition-dependent infants with cholestasis who are not adequately growing on 1 g/kg/day of soy-based lipid emulsion must have a greater intake of lipids to meet their needs for weight, length, and head circumference growth. SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids. The utility of Omegaven and soy-based lipid emulsion is limited as these are restricted to 1 g/kg/day in cholestatic infants. SMOFlipid is safe to be provided at the usual goal infusion amount of 3 g/kg/day. Because this product includes both omega-6 and omega-3 lipids, it provides the benefits of the omega-3s for the liver and provides more than enough omega-6s to meet essential fatty acid requirements. Its use in situations in which growth is inadequate in babies who must be restricted to 1 g/kg/day can be expected to improve their growth and likely markedly increase their chances of both a good neurological outcome and survival. The aim of this research study is to determine if the unique formulation of SMOFLipid will cause less hepatic inflammation compared to soy only intralipids.

NCT ID: NCT02477228 Completed - Clinical trials for Jaundice, Obstructive

Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation

ERCP
Start date: January 2014
Phase: N/A
Study type: Interventional

Endoscopic sphincterotomy is now an established method for removal of common bile duct calculi and treatment of papillary stenosis, the sump syndrome and certain cases of ampullary carcinoma. It is also generally performed prior to biliary stent placement .Anatomical variations, papillary stenosis, impacted stones, ampullary tumors, duodenal diverticula, and post-gastrojejunostomy states are some of the reasons behind difficult common bile duct (CBD) cannulations . In these situations, the success of CBD cannulation can be enhanced slightly by using the various accessories designed for this purpose.The aim of this study is to prospectively compare conventional approach and needle knife fistulotomy in cannulation of ampulla of Vater during endoscopic retrograde cholangiopancreatography regarding procedure-related complications as failure of cannulations, bleeding and perforation and postoperative complication

NCT ID: NCT02468076 Completed - Cholangiocarcinoma Clinical Trials

Radiofrequency Ablation for Biliopancreatic Malignancy

IGNITE-1
Start date: November 2014
Phase: Phase 2
Study type: Interventional

This phase-2 study aims to evaluate feasibility, safety and efficacy of thermal ablation of biliary obstructive malignancies by means of radiofrequency ablation (RFA, ELRA, StarMed) during endoscopic retrograde cholangio-pancreaticography (ERCP) with primary intent to obtain palliative biliary drainage via stenting

NCT ID: NCT02166840 Completed - Clinical trials for Obstructive Jaundice

Metal or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors.

SEMS
Start date: March 2007
Phase: Phase 2
Study type: Interventional

Patients with obstructive jaundice due to periampullary tumor can temporarily be relieved of their jaundice with transpapillary stenting at endoscopic retrograde cholangio-pancreatography (ERCP) prior to operation. Usually plastic stents are used. Hypothesis: Self expanding metallic stents offer a be a better alternative for preoperative stenting in patients with obstructive jaundice due to periampullary tumour obstruction.

NCT ID: NCT01675908 Completed - Pancreatic Cancer Clinical Trials

Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression

Start date: August 22, 2012
Phase: N/A
Study type: Interventional

Compare the performance of full covered metal stents and plastic stents for preoperative biliary decompression

NCT ID: NCT01506115 Completed - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma

Start date: September 2009
Phase: N/A
Study type: Interventional

The prognosis of patients with obstructive jaundice caused by hepatocellular carcinoma (HCC) is dismal even after biliary drainage; due to malfunction of the biliary drainage tube caused by hemobilia and/or tumor emboli. Photodynamic therapy (PDT) in hilar cholangiocarcinoma improves biliary drainage and prolongs survival. The aims of this study were to assess the safety and efficacy of PDT in unresectable HCC with bile duct invasion.

NCT ID: NCT01321203 Completed - Clinical trials for Obstructive Jaundice

Outcome of Carbon Dioxide Versus Air Insufflations During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Start date: August 2010
Phase: N/A
Study type: Observational

To assess the safety and efficacy of CO2 insufflations during ERCP 1. Primary objective: To assess the patient's symptoms, abdominal pain and abdominal distension post procedure (ERCP) in the study group. 2. Secondary objective: Endoscopist: - To assess the adequacy of bowel distension for adequate luminal visualization - To assess the peristaltic movement during the ERCP Anesthetist: - To measure the PCO2 level in patient post procedure. - To assess the amount of sedation required during the procedure. - To assess saturation and vital signs through out the procedure. - To assess requirement of buscopan.

NCT ID: NCT01315522 Completed - Clinical trials for Biliary Tract Neoplasms

Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents

Start date: June 2010
Phase: Phase 4
Study type: Interventional

Endoscopic retrograde biliary drainage (ERBD) is now widely accepted as the standard intervention for the relief of obstructive jaundice in patients with unresectable malignant biliary obstruction. Although plastic stents (PSs) were developed earlier, self-expandable metal stents (SEMSs) are now used widely as the initial choice for ERBD in this setting, as SEMSs offer longer patency.However, SEMSs do become occluded in some patients. There are a limited number of reports on the management of occluded SEMS with various results. The aim of this study is to compare the efficacy of ComVi stents SEMSs with uncovered SEMS in subsequent ERBD after the occlusion of initial SEMSs.